Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals Inc., USA will launch 8.4% Sodium Bicarbonate Injection USP (50 mEq/50 mL single-dose vial) in the US market starting November 2025. The product is bioequivalent and therapeutically equivalent to the reference listed drug from Abbott Laboratories. According to IQVIA data for the 12 months ending August 2025, the addressable US market for this injection is approximately $63.8 million annually. This expands Glenmark's injectable portfolio in North America and adds an affordable alternative for patients.
This is a positive development as it strengthens Glenmark's US generics business and adds another product in a meaningful market. The $63.8 million addressable market offers growth potential, though actual revenue capture by Glenmark will depend on competition and market share gained.